Nonclinical Safety Profile of Revusiran, a 1st-Generation GalNAc-siRNA Conjugate for Treatment of Hereditary Transthyretin-Mediated Amyloidosis

Revusiran is a 1st-generation short interfering RNA targeting transthyretin conjugated to an N-acetylgalactosamine ligand to facilitate delivery to hepatocytes via uptake by the asialoglycoprotein receptors. Revusiran, in development for the treatment of hereditary transthyretin-mediated amyloidosis...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nucleic Acid Ther
Main Authors: Sutherland, Jessica E., Hettinger, Julia L., Chan, Amy, Gilbert, Jason, Warner, Garvin L., Davis, Wendell P.
Formato: Artigo
Idioma:Inglês
Publicado em: Mary Ann Liebert, Inc., publishers 2020
Assuntos:
Original Papers
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6987735/
https://ncbi.nlm.nih.gov/pubmed/31821125
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/nat.2019.0796
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados